<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140255</url>
  </required_header>
  <id_info>
    <org_study_id>IMPAACT P1115</org_study_id>
    <secondary_id>UM1AI068632</secondary_id>
    <secondary_id>UM1AI068616</secondary_id>
    <secondary_id>UM1AI106716</secondary_id>
    <nct_id>NCT02140255</nct_id>
  </id_info>
  <brief_title>IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission</brief_title>
  <official_title>IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPAACT P1115 will explore the effects of early intensive antiretroviral therapy (ART) on
      achieving HIV remission (HIV RNA below the limit of detection of the assay) among
      HIV-infected infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMPAACT P1115 will explore the effects of early intensive ART on achieving HIV remission (HIV
      RNA below the limit of detection of detection of the PCR assay) among infants infected with
      HIV in utero. Infants in this study will initiate ART within 48 hours of birth and will first
      be evaluated to determine whether HIV RNA can be detected in their blood while they are on
      ART. Upon reaching two years of age, infants with undetectable HIV RNA will be evaluated to
      determine if they meet study criteria to stop taking ART. Infants who meet these criteria
      will stop taking ART and will be monitored closely to determine whether HIV RNA remains
      undetectable while they are off ART. For any infant who stops ART and then has HIV RNA
      detected, ART will be re-started.

      The study will also assess the safety and pharmacokinetics of early intensive ART in infants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV remission</measure>
    <time_frame>48 weeks after ART cessation</time_frame>
    <description>No confirmed HIV RNA at or above the level of detection of the RNA PCR assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through 5 years of age</time_frame>
    <description>Grade 3, 4, and 5 signs, symptoms, laboratory values, and diagnoses assessed as possibly, probably, or definitely related to one or more ARVs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Early Intensive ART</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive ART regimen</intervention_name>
    <description>Nucleoside reverse transcriptase inhibitor (1) chosen by clinician
Nucleoside reverse transcriptase inhibitor (2) chosen by clinician
Nevirapine
Lopinavir boosted with ritonavir</description>
    <arm_group_label>Early Intensive ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. COHORT 1 MOTHERS

               -  Presumed or confirmed HIV infection (if presumed, must be confirmed within 7 days
                  after study entry)

               -  No receipt of ARVs during the current pregnancy.

               -  Willing and able to provide written informed consent for maternal and infant
                  study participation

          2. COHORT 1 INFANTS

               -  ≤ 48 hours of age

               -  ≥ 34 weeks gestational age at birth

               -  Able to take ARVs by mouth, nasogastric tube, or gastrostomy tube

          3. COHORT 2 MOTHERS

               -  Presumed or confirmed HIV infection (if presumed, must be confirmed within 7 days
                  after study entry)

               -  Willing and able to provide written informed consent for maternal and infant
                  study participation

          4. COHORT 2 INFANTS

               -  ≤ 10 days of age

               -  ≥ 34 weeks gestational age at birth

               -  ≥ one nucleic acid test positive for HIV infection on a sample drawn within 48
                  hours of birth

               -  Started ART within 48 hours of birth on a regimen including 2 NRTIs plus NVP at a
                  dose of at least 8 mg/day for infants weighing ≤ 2 kg or 12 mg/day for infants &gt;
                  2 kg AND/OR LPV/r

               -  ART regimen was taken daily from date of initiation until study entry

               -  Able to take ARVs by mouth, nasogastric tube, or gastrostomy tube

        Exclusion Criteria:

        INFANTS

          -  Any clinically significant diseases (other than HIV infection) or clinically
             significant findings during review of medical history or physical examination prior to
             entry that, in the investigator's opinion, would interfere with study participation or
             interpretation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Bryson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellen Chadwick, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University Feinberg School of Medicine and Ann &amp; Robert Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Coletti, MS</last_name>
    <phone>919-544-7040</phone>
    <phone_ext>11238</phone_ext>
    <email>acoletti@fhi360.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Diagnostic and Treatment Center(5055)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Puga, MD</last_name>
      <phone>954-728-1017</phone>
      <email>apuga@browardhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Zulma Eysallenne, RN</last_name>
      <phone>954-728-1125</phone>
      <email>zeysallenne@browardhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ana Puga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Center for HIV/AIDS Research, Education, and Service (5051)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mobeen Rathore, MD</last_name>
      <phone>904-244-2120</phone>
      <email>mobeen.rathore@jax.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tabetha Gayton, RN, PhD</last_name>
      <phone>904-244-5331</phone>
      <email>tabetha.gayton@jax.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mobeen Rathore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Pediatric/Perinatal HIV Clinical Research Site (4201)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwendolyn Scott, MD</last_name>
      <phone>305-243-6522</phone>
      <email>gscott@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Bryan, RN</last_name>
      <phone>305-243-2700</phone>
      <email>pbryan@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gwendolyn Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (4001)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Chadwick, MD</last_name>
      <phone>312-227-4080</phone>
      <email>egchadwick@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Ann Sanders, MPH</last_name>
      <phone>312-227-8275</phone>
      <email>msanders@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ellen Chadwick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine (5092)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Agwu, MD, MS</last_name>
      <phone>410-614-3917</phone>
      <email>ageorg10@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thuy Anderson, RN, BSN</last_name>
      <phone>443-287 8942</phone>
      <email>tander34@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Allison Agwu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center (5011)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cooper Ellen, MD</last_name>
      <phone>617-414-5588</phone>
      <email>ercooper@bu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Debra McLaud, RN</last_name>
      <phone>617-414-5813</phone>
      <email>demclaud@bmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ellen Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook University Medical Center (5040)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Nachman, MD</last_name>
      <phone>631-444-7692</phone>
      <email>sharon.nachman@sbumed.org</email>
    </contact>
    <contact_backup>
      <last_name>Denise Ferraro</last_name>
      <phone>631-444-8225</phone>
      <email>denise.ferraro@stonybrook.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sharon Nachman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center (5013)</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wiznia, MD</last_name>
      <phone>718-918-4903</phone>
      <email>andrew.wiznia@einstein.yu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marlene Burey</last_name>
      <phone>718-918-4783</phone>
      <email>marlene.burey@nbhn.net</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Wiznia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital (6501)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Knapp, MD</last_name>
      <phone>901-448-4774</phone>
      <email>Katherine.knapp@stjude.org</email>
    </contact>
    <contact_backup>
      <last_name>Jill Utech, MSN, CCRC</last_name>
      <phone>901-595-3490</phone>
      <email>jill.utech@stjude.org</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Knapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital (5031)</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Midnela Acevedo-Flores, MT, MD</last_name>
      <phone>787-764-3083</phone>
      <email>macevedo@sanjuanciudadpatria.com</email>
    </contact>
    <contact_backup>
      <last_name>Elvia Perez, BS, MA, MPH</last_name>
      <phone>787-764-3083</phone>
      <email>eperez@sanjuanciudadpatria.com</email>
    </contact_backup>
    <investigator>
      <last_name>Midnela Acevedo-Flores, MT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.impaactnetwork.org/studies/P1115.asp</url>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

